Brightline-1: When a Negative Trial Reveals Two Active Therapies

Authors
Category Primary study
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Year 2026
Although Brightline-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with the median PFS of 8.4 months, objective response rate of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in dedifferentiated liposarcoma.
Epistemonikos ID: c630e452ecb08ea2ea070e6e9af942deae67be6e
First added on: Aug 15, 2026